| Autor: |
Benjamin Heidrich, Steffen B Wiegand, Peter Buggisch, Holger Hinrichsen, Ralph Link, Bernd Möller, Klaus H W Böker, Gerlinde Teuber, Hartwig Klinker, Elmar Zehnter, Uwe Naumann, Heiner W Busch, Benjamin Maasoumy, Undine Baum, Svenja Hardtke, Michael P Manns, Heiner Wedemeyer, Jörg Petersen, Markus Cornberg, HepNet Study Group |
| Jazyk: |
angličtina |
| Rok vydání: |
2014 |
| Předmět: |
|
| Zdroj: |
PLoS ONE, Vol 9, Iss 10, p e108751 (2014) |
| Druh dokumentu: |
article |
| ISSN: |
1932-6203 |
| DOI: |
10.1371/journal.pone.0108751 |
| Popis: |
Evidence based clinical guidelines are implemented to treat patients efficiently that include efficacy, tolerability but also health economic considerations. This is of particular relevance to the new direct acting antiviral agents that have revolutionized treatment of chronic hepatitis C. For hepatitis C genotypes 2/3 interferon free treatment is already available with sofosbuvir plus ribavirin. However, treatment with sofosbuvir-based regimens is 10-20 times more expensive compared to pegylated interferon alfa and ribavirin (PegIFN/RBV). It has to be discussed if PegIFN/RBV is still an option for easy to treat patients. We assessed the treatment of patients with chronic hepatitis C genotypes 2/3 with PegIFN/RBV in a real world setting according to the latest German guidelines. Overall, 1006 patients were recruited into a prospective patient registry with 959 having started treatment. The intention-to-treat analysis showed poor SVR (GT2 61%, GT3 47%) while patients with adherence had excellent SVR in the per protocol analysis (GT2 96%, GT3 90%). According to guidelines, 283 patients were candidates for shorter treatment duration, namely a treatment of 16 weeks (baseline HCV-RNA |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
